Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clostridium ghonii spores
- Development stage
- Unknown
- Lead developer
- Shandong Xinchuang Biotechnology
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intratumoral
01
Overview
Clostridium ghonii spores is an investigational oncolytic bacterial therapy developed by Shandong New Creation Biotechnology for the treatment of advanced solid tumors, including soft tissue sarcoma. The therapy utilizes the unique properties of *Clostridium ghonii*, an obligate anaerobic bacterium. When administered via intratumoral injection, the spores remain dormant in oxygenated tissues but selectively germinate into vegetative bacteria within the hypoxic and necrotic regions characteristic of solid tumors. These bacteria then proliferate and cause direct lysis of tumor cells, a process known as bacteriolysis. Beyond direct destruction, the localized bacterial infection is designed to stimulate the host's immune system, potentially converting 'cold' tumors into 'hot' tumors and inducing a systemic anti-tumor response.
- Other names
- CG sporesClostridium ghonii
Beyond the preview
Go deeper on Clostridium ghonii spores.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Clostridium ghonii spores.